Actively Recruiting
Phase III Open-Label Study of ECI830 Alone or With Ribociclib and Fulvestrant for Advanced HRHER2- Breast Cancer and Other Solid Tumors
Led by Novartis Pharmaceuticals · Updated on 2026-08-27
280
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating ECI830 as a single treatment and in combination with ribociclib and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative HRHER2- breast cancer and other advanced solid tumors. This phase III, open-label, multi-center study aims first to assess safety, tolerability, and dosing of ECI830 alone and with other drugs, then to evaluate its anti-tumor effects in combination therapy for advanced breast cancer patients. Participants will receive ECI830 either alone or combined with ribociclib and fulvestrant. The study involves dose escalation and expansion phases, including a randomized phase II portion for combination therapy with possible dose optimization. Treatments are given according to specific regimens for different patient groups, focusing on those with advanced HRHER2- breast cancer, CCNE1-amplified solid tumors, or extensive-stage small cell lung cancer. During the trial, participants will undergo various assessments including monitoring for dose-limiting toxicities, adverse events, and treatment interruptions over two years. Tumor response will be evaluated using standardized imaging criteria at set intervals, along with pharmacokinetic measurements of drug levels. Safety and effectiveness outcomes will be followed for up to two years, with careful observation and data collection throughout the study period.
CONDITIONS
Brief Title
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here